Based on these findings, monoclonal antibodies targeting the IL-17 and IL-6 signalling pathways, targeting neutrophil activity, systemic corticosteroids and broad activity immunomodulatory drugs can help dampen the hyper-inflammatory events that are driven by neutrophils in COVID-19 patients. Here, IL17A is linked to COVID-19.